Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening

• Published in: International journal of molecular sciences Vol. 23; no. 12; p. 6630
• Main Authors: Pedrucci, Federica, Pappalardo, Claudia, Marzaro, Giovanni, Ferri, Nicola, Ferlin, Alberto, De Toni, Luca
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14.06.2022; MDPI
• Subjects: Autoimmune diseases; Binding; Binding sites; Biological activity; Clinical trials; Dialectics; Drug development; Efficiency; Enzymes; Gene expression; Kinases; Ligands; Lipinski rule of five; Modular design; molecular glue; Pharmacodynamics; Pharmacokinetics; Pharmacology; Prostate cancer; Proteasome Endopeptidase Complex - metabolism; Proteasomes; Protein Binding; Proteins; Proteolysis; Review; thalidomide; Thrombocytopenia; Ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination; Von Hippel-Lindau; warhead; United States > US; Von Hippel-Lindau; molecular glue; warhead; thalidomide; Lipinski rule of five
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23126630

From seminal evidence in the early 2000s, the opportunity to drive the specific knockdown of a protein of interest (POI) through pharmacological entities called Proteolysis Targeting Chimeric molecules, or PROTACs, has become a possible therapeutic option with the involvement of these compounds in clinical trials for cancers and autoimmune diseases. The fulcrum of PROTACs pharmacodynamics is to favor the juxtaposition between an E3 ligase activity and the POI, followed by the ubiquitination of the latter and its degradation by the proteasome system. In the face of an apparently modular design of these drugs, being constituted by an E3 ligase binding moiety and a POI-binding moiety connected by a linker, the final structure of an efficient PROTAC degradation enhancer often goes beyond the molecular descriptors known to influence the biological activity, specificity, and pharmacokinetics, requiring a rational improvement through appropriate molecular strategies. Starting from the description of the basic principles underlying the activity of the PROTACs to the evaluation of the strategies for the improvement of pharmacodynamics and pharmacokinetics and rational design, this review examines the molecular elements that have been shown to be effective in allowing the evolution of these compounds from interesting proof of concepts to potential aids of clinical interest.